$BIIB Income Statement | Understand Stock

$BIIB

$252.26 +$1.57 (0.63%) Close

$BIIB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Income

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Product revenue, net
Other
Revenue from anti-CD20 therapeutic programs
Alzheimer's collaboration revenue
Contract manufacturing, royalty and other revenue
Total revenues

Cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets
Research and development
Acquired in-process research and development, upfront and milestone expense
Selling, general and administrative
(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations
Amortization and impairment of acquired intangible assets
Collaboration profit sharing/(loss reimbursement)
(Gain) loss on fair value remeasurement of contingent consideration
Acquired in-process research and development
Impairment of ROU asset
Restructuring charges
Gain on sale of priority review voucher, net
Gain on sale of building, net
Other (income) expense, net
Total cost and expense

Income from operations
Income before income tax (benefit) expense
Income tax (benefit) expense
Equity in (income) loss of investee, net of tax
Net income
Net income attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.
Net income per share:
Basic earnings per share attributable to Biogen Inc. (in dollars per share)
Diluted earnings per share attributable to Biogen Inc. (in dollars per share)
Weighted-average shares used in calculating:
Weighted-average number of common shares outstanding (in shares)
Diluted earnings per share attributable to Biogen Inc. (in shares)

Comments